Peroxisome proliferator-activated receptor (PPAR) agonists improve glucose control and insulin sensitivity, reduce concentrations of atherogenic lipoproteins, and decrease circulating levels of inflammatory mediators. PPAR activation is considered an important pharmacologic target for patients with type 2 diabetes. However, the PPAR agonists in clinical use have undesirable side effects, including weight gain, heart failure, and bone fractures. PPAR α/γ dual agonists each target one or more of the key cardiometabolic risk factors of diabetic dyslipidemia, insulin resistance, hyperglycemia, and inflammation; thus, combining their benefits to provide glucose control and ameliorate cardiovascular risks has emerged as an attractive treatment option. Aleglitazar, which was designed to balance the activation of PPAR α/γ, proved efficacious in improving glycemic control and lipid homeostasis and is anticipated to minimize PPAR-related side effects. Whether the effects of aleglitazar on cardiometabolic risk factors translate into improved cardiovascular outcomes, particularly in high-risk patients, is currently being evaluated by AleCardio, a large, long-term, time-, and event-driven outcome study of type 2 diabetics with recent acute coronary syndrome. ( 
) [16, 19] .
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공복혈당의 감소는 약물 투여 2주 뒤에 나타나고 8주에
공복혈당 저하와 고밀도 지단백 콜레스테롤 상승 효과가 최 
Arrows denote semi-quantitative comparisons among PPAR-α agonists, PPAR-γ agonists and aleglitazar (↔ = no change). PPAR, Peroxisome proliferator-activated receptor; HbA1c, Hemoglobin A1c; HDL-C, High-density lipoprotein-cholesterol; LDL-C, Low-density lipoprotein-cholesterol. Table 2 . Side effects of PPAR α and γ agonists and aleglitazar, a dual PPAR α/γ agonist.
PPAR-α PPAR-γ Aleglitazar
Serum creatinine
Arrows denote semi-quantitative comparisons among PPAR-α agonists, PPAR-γ agonists and aleglitazar (↔ = no change). PPAR, Peroxisome proliferator-activated receptor. 
